SEC Form 4 · accession 0000929638-26-002256
enGene Therapeutics Inc. · ENGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lota S. Zoth
Director
Period of report
Jun 16, 2026
Accepted (ET)
Jun 17, 2026 · 5:35 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001980845
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.75 | Jun 16, 2026 | A | 31,000 | A | — | Jun 16, 2036 | Common Shares | 31,000 | 31,000 | D |
Explanation of responses
- F1This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.